Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Brand-name prescription medicine

Rowasa

Generic name: Mesalamine

FDA application holder: Mylan Speciality LP

Official data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the NDC Directory, Drugs@FDA, the official labels and recall reports; pharmacy costs come from the Centers for Medicare & Medicaid Services (CMS). Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or switch any medicine, including a switch between a brand and a generic.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Quick answers

What is Rowasa?
Rowasa is a brand name of Mesalamine, a prescription medicine. The FDA NDC Directory lists 1 Rowasa product in 1 strength and form.
Who makes Rowasa?
Mylan Speciality LP holds the FDA application for Rowasa (NDA019618, approved December 24, 1987).
Is there a generic or store brand of Rowasa?
Yes. The FDA NDC Directory lists 4 other products with the same active ingredients, strength and form as a Rowasa product, 4 of them generic. Ask your pharmacist whether one is right for you.
Has Rowasa been recalled?
No recall linked to Rowasa products (by their NDC code or label) appears in the FDA enforcement reports we use.

What Rowasa is

Each Rowasa product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.

Mesalamine · prescription medicine

Strength and formProduct namesSame medicine, other namesLabel
mesalamine 4 g/60 mL
suspension (rectal)
Rowasa 4 products, 4 companies DailyMed

Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Mesalamine →

FDA approval

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
FDA applications of Rowasa products (Drugs@FDA)
ApplicationHolderFirst approvedProducts
NDA019618Mylan Speciality LPDecember 24, 19871

Companies that list Rowasa

The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of Rowasa products.

Recalls

No recall linked to Rowasa products (by their NDC code or label) appears in the FDA enforcement reports.

Sources

  1. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  2. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  3. Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
  5. NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026

Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.

Report an error → · Information for medicine makers